Oxyntomodulin activates both the GLP-1 and glucagon receptors simultaneously, potentially offering better weight loss and blood sugar control than GLP-1 drugs alone.
Dual receptor agonist: GLP-1R + glucagon receptorOXM combines appetite suppression with increased energy expenditure — something GLP-1-only drugs don't fully achieve
What the researchers found
Oxyntomodulin (OXM) is a gut-derived peptide that acts as a dual agonist of both the GLP-1 receptor and the glucagon receptor. This review summarizes evidence that OXM injections in humans cause significant reductions in weight and appetite while increasing energy expenditure — a combination that single GLP-1 receptor agonists don't fully achieve. Although glucagon receptor activation normally raises blood sugar (potentially harmful in diabetics), the simultaneous GLP-1 receptor activation counteracts this effect. In diet-induced obese mice, OXM improved glucose tolerance. The dual agonist approach may offer enhanced weight loss and better glycemic control compared to GLP-1 agonists alone.
Why it matters
This review foreshadowed the dual and multi-agonist drugs now in development (like survodutide and other GLP-1/glucagon dual agonists). It laid out the scientific rationale for why combining GLP-1 and glucagon receptor activity could be more effective for obesity and diabetes than targeting GLP-1 alone — an idea that has since driven a major wave of pharmaceutical development.
How the study worked
This is a narrative review article synthesizing published research on oxyntomodulin's pharmacology, including human injection studies, mouse models of diet-induced obesity, and receptor binding data. No new experimental data were generated.
Who was studied
Review article (no direct study population)
What this study cannot tell us
As a review article, this does not present new experimental data. The human evidence for OXM cited was based on relatively small, short-term injection studies. The clinical translation of dual agonism was still theoretical at the time of publication, with no approved dual-agonist drugs available.
How to read the evidence
This is a narrative review article, not an original study. It synthesizes evidence from human and animal studies but does not generate new data. The concepts have since been validated by clinical development of dual agonist drugs.
When this study was published
Published in 2012 in the Journal of Endocrinology. While the review itself is over a decade old, its core thesis — that dual GLP-1/glucagon agonism is superior to GLP-1 alone — has been strongly validated by subsequent drug development.
The bigger picture
This 2012 review was ahead of its time. The concept it describes — dual receptor agonism for metabolic disease — has since become one of the hottest areas in drug development. Tirzepatide (a GLP-1/GIP dual agonist) became a blockbuster, and several GLP-1/glucagon dual agonists (like survodutide and mazdutide) are now in clinical trials. Oxyntomodulin itself served as the natural proof of concept that the body already uses multi-receptor peptide signaling to regulate metabolism.
Questions still open
- Can synthetic OXM analogs achieve the same dual-agonist benefits with better pharmacokinetics for clinical use?
- How does the weight loss from GLP-1/glucagon dual agonists compare to GLP-1/GIP dual agonists like tirzepatide?
- Is the glucagon receptor component safe for patients with more advanced type 2 diabetes?
Common questions
What makes oxyntomodulin different from semaglutide?
If glucagon raises blood sugar, isn't a glucagon receptor agonist dangerous for diabetics?
Read the original research
Unraveling oxyntomodulin, GLP1's enigmatic brother.
The Journal of endocrinology, 215(3), 335-46
Citation
Pocai, Alessandro. (2012). Unraveling oxyntomodulin, GLP1's enigmatic brother.. The Journal of endocrinology, 215(3), 335-46. https://doi.org/10.1530/JOE-12-0368